Ephrin-A1 promotes the malignant progression of intestinal tumors in Apcmin/+ mice

Oncogene

Volumn 27, Issue 23, 2008, Pages 3265-3273

  Shi, L ^a   Itoh, F ^a   Itoh, S ^a   Takahashi, S ^a   Yamamoto, M ^b,c   Kato, M ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Apcmin + mice; Ephrin A1; Intestinal adenoma; Invasion

Indexed keywords

APC PROTEIN; EPHRIN A1; EPHRIN A2;

ADENOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INVASION; CONTROLLED STUDY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; INTESTINE CANCER; INTESTINE TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH;

ADENOMA; ANIMALS; DISEASE PROGRESSION; EPHRIN-A1; FATTY ACID-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, APC; HUMANS; INTESTINAL MUCOSA; INTESTINAL NEOPLASMS; MICE; MICE, TRANSGENIC; NEOPLASM INVASIVENESS; NEOPLASMS, MULTIPLE PRIMARY; RECOMBINANT FUSION PROTEINS; TUMOR BURDEN;

MUS; MUS MUSCULUS;

EID: 44349089921     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210992     Document Type: Article

References (37)

1. Abraham S, Knapp DW, Cheng L, Snyder PW, Mittal SK, Bangari DS et al. (2006). Expression of EphA2 and ephrin-A1 in carcinoma of the urinary bladder. Clin Cancer Res 12: 353-360.
2. Batlle E, Bacani J, Begthel H, Jonkheer S, Gregorieff A, van de Born M et al. (2005). EphB receptor activity suppresses colorectal cancer progression. Nature 435: 1126-1130.
3. Brantley-Sieders DM, Fang WB, Hicks DJ, Zhang G, Shyr Y, Chen J. (2005). Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J 9: 1884-1886.
4. Brantley-Sieders DM, Fang WB, Hwang Y, Hicks D, Chen J. (2006). Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice. Cancer Res 66: 10315-10324.
5. Coffman KT, Hu M, Carles-Kinch K, Tice D, Donacki N, Munyon K et al. (2003). Differential EphA2 epitope display on normal versus malignant cells. Cancer Res 63: 7907-7912.
6. de Bruine AP, Wiggers T, Beek C, Volovics A, von Meyenfeldt M, Arends JW et al. (1993). Endocrine cells in colorectal adenocarcinomas: incidence, hormone profile and prognostic relevance. Int J cancer 9: 765-771.
7. Dobrzanski P, Hunter K, Jones-Bolin S, Chang H, Robinson C, Pritchard S et al. (2004). Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res 64: 910-919.
8. Eph Nomenclature Committee (1997). Unified nomenclature for Eph family receptors and their ligands, the ephrins. Cell 90: 403-404.
9. Hamamoto T, Beppu H, Okada H, Kawabata M, Kitamura T, Miyazono K et al. (2002). Compound disruption of Smad2 accelerates malignant progression of intestinal tumors in Apc knockout mice. Cancer Res 62: 5955-5961.
10. Herath NJ, Spanevello MD, Sabesan S, Newton T, Cummings M, Duffy S. (2006). Over-expression of Eph and ephrin genes in advanced ovarian cancer: ephrin gene expression correlates with shortened survival. BMC cancer 6: 144.
11. Huusko P, Ponciano-Jackson D, Wolf M, Kiefer JA, Azorsa DO, Tuzmen S et al. (2004). Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nature Genet 36: 979-983.
12. Kataoka H, Igarashi H, Kanamori M, Ihara M, Wang JD, Wang YJ et al. (2004). Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer. Cancer Sci 95: 136-141.
13. Kullander K, Klein R. (2002). Mechanisms and functions of Eph and ephrin signaling. Nat Rev Mol Cell Biol 3: 475-486.
14. Liu DP, Wang Y, Koeffler HP, Xie D. (2007). Ephrin-A1 is a negative regulator in glioma through down-regulation of EphA2 and FAK. Int J Oncol 30: 865-871.
15. + in intestinal adenomas from Min mice. Cancer Res 54: 5947-5952.
16. Mellitzer G, Xu Q, Wilkinson DG. (1999). Eph receptors and ephrins restrict cell intermingling and communication. Nature 400: 77-81.
17. Murai KK, Pasquale EB. (2003). 'Eph'ective signaling: forward, reverse and crosstalk. J Cell Sci 116: 2823-2832.
18. Nakamura R, Kataoka H, Sato N, Kanamori M, Ihara M, Igarashi H et al. (2005). EPHA2/EFNA1 expression in human gastric cancer. Cancer Sci 96: 42-47.
19. Noren NK, Foos G, Hauser CA, Pasquale EB. (2006). The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol 8: 815-825.
20. Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB. (2000). The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 19: 6043-6052.
21. Parri M, Buricchi F, Taddei ML, Giannoni E, Raugei G, Ramponi G et al. (2005). EphrinA1 repulsive response is regulated by EphA2 tyrosine phosphatase. J Biol Chem 280: 34008-340018.
22. Pasquale EB. (2005). Eph receptor signaling casts a wide net on cell behavior. Nat Rev Mol Cell Biol 6: 462-475.
23. Potla L, Boghaert ER, Armellino D, Frost P, Damle NK. (2002). Reduced expression of Ephrin-A1 (EFNA1) inhibits three-dimensional growth of HT29 colon carcinoma cells. Cancer Lett 175: 187-195.
24. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN et al. (1992). APC mutations occur early during colorectal tumorigenesis. Nature 359: 235-237.
25. Saam JR, Gordon JI. (1999). Inducible gene knockouts in the small intestinal and colonic epithelium. J Biol Chem 274: 38071-38082.
26. Simon TC, Cho A, Tso P, Gordon JI. (1997). Suppressor and activator functions mediated by a repeated heptad sequence in the liver fatty acid-binding protein gene (Fabpl). J Biol Chem 272: 10652-10663.
27. Straume O, Akslen LA. (2005). Strong expression of ID1 protein is associated with decreased survival, increased expression of ephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma. Br J Cancer 93: 933-938.
28. Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C et al. (1992). Multiple intestinal neoplasia caused by a mutation in the murine homolog of APC. Science 256: 668-670.
29. Surawska H, Ma PC, Salgia R. (2004). The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev 15: 419-433.
30. Swatek J, Chibowski D. (2000). Endocrine cells in colorectal carcinomas. Immunohistochemical study. Pol J Pathol 51: 127-136.
31. Takaku K, Oshima M, Miyoshi H, Matsui M, Seldin MF, Taketo MM. (1998). Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell 92: 645-656.
32. Vogelstein B. (1990). Cancer. A deadly inheritance. Nature 348: 681-682.
33. Wang Y-j, Ota S, Kataoka H, Kanamori M, Li Z-y, Band H et al. (2002). Negative regulation of EphA2 receptor by Cbl. Biochem Biophys Res Commun 296: 214-220.
34. Wu D, Suo Z, Kristensen GB, Li S, Troen G, Holm R et al. (2004). Prognostic value of EphA2 and Ephrin-A1 in squamous cell cervical carcinoma. Gynecol Oncol 94: 312-319.
35. Xu F, Zhong W, Li J, Shanshen Z, Cui J, Nesland JM et al. (2005). Predictive value of EphA2 and ephrin-A1 expression in oesophageal squamous cell carcinoma. Anticancer Res 25: 2943-2950.
36. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C et al. (2004). Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117: 927-939.
37. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. (2001). EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 61: 2301-2306.